Editas Medicine reported positive first-quarter 2026 results, highlighting progress on EDIT-401, a gene-editing therapy aimed at treating hyperlipidemia by significantly reducing LDL cholesterol and other cardiovascular risk factors in preclinical studies. The company plans to start first-in-human trials for EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia later this year, with early proof-of-concept data expected by year-end 2026. Financially, Editas reduced its net loss compared to the previous year and maintains sufficient cash to fund operations into late 2027. The company also confirmed a favorable patent decision supporting its CRISPR technology rights. Upcoming presentations will share new preclinical data at major scientific conferences.
The Schall Law Firm is investigating UP Fintech Holding Limited for possible securities law violations after a Reuters report revealed China's crackdown on illegal cross-border securities trading. The report accused UP Fintech's Tiger subsidiary of o...
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Guardian Exploration Inc. completed a private placement, raising $1.72 million by issuing 6.89 million units at $0.25 each. Each unit includes one flow-through common share and one warrant exercisable at $0.40 for two years. The funds will support ex...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
The 2026 China (Jinhua Mountain) International Camping Congress was held from May 16-17 in Zhejiang Province, focusing on integrating culture, sports, tourism, and industry to promote high-quality development of camping tourism and leisure. The event...
